Analysis of 10 years drug lifecycle management (LCM) activities in the Japanese market
Authors:
- Yukiko HashiteraYHYukiko Hashitera
- Chikako SaotomeCSChikako Saotome
- Hirokazu YamamotoHYHirokazu Yamamoto
- 1 November 2013
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 18 (21-22) , 1109-1116
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Drug buddiesNature, 2011
- Industry gives cautious welcome to NIH translational centerNature Biotechnology, 2011
- Francis CollinsNature Reviews Drug Discovery, 2010
- The importance of new companies for drug discovery: origins of a decade of new drugsNature Reviews Drug Discovery, 2010
- Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled studyThe Journal of Dermatology, 2010
- The Emerging Academic Drug-Discovery SectorFuture Medicinal Chemistry, 2009
- Product-related research: how research can contribute to successful life-cycle managementDrug Discovery Today, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- One target – multiple indications: a call for an integrated common mechanisms strategyDrug Discovery Today, 2007
- Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedAnnals of the Rheumatic Diseases, 2004